Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma
- 14 November 2019
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 30 (3) , 1679-1689
Abstract
Objectives To evaluate the feasibility of equilibrium contrast-enhanced dual-energy CT (DECT), as compared with single-energy CT (SECT) and to calculate extracellular volume (ECV) fraction to predict the survival outcomes of pancreatic ductal adenocarcinoma (PDAC) patients with distant metastases (stage IV) treated with chemotherapy. Methods The study cohort included a total of 66 patients with stage IV PDAC who underwent DECT before systemic chemotherapy between July 2014 and March 2017. Unenhanced and 120-kVp equivalent images during the equilibrium phase were used to calculate tumor SECT-derived ECV fractions, and iodine density images were obtained from equilibrium-phase DECT for DECT-derived ECV fractions. Correlations between SECT- and DECT-derived ECV fractions were identified using the Pearson correlation coefficient and Bland–Altman analysis. The effects of clinical prognostic factors and tumor SECT- and DECT-derived ECV fractions on progression-free survival (PFS) and overall survival (OS) were assessed by univariate and multivariate analyses using Cox proportional hazards models. Results The correlation between SECT- and DECT-derived ECV fractions was strong (r = 0.965; p < 0.001). The Bland–Altman plot between SECT- and DECT-derived ECV fractions showed a small bias (− 3.4%). Increasing tumor SECT- and DECT-derived ECV fractions were associated with a positive effect on PFS (SECT, p = 0.002; DECT, p = 0.007) and OS (DECT, p = 0.014; DECT, p = 0.015). Only tumor DECT-derived ECV fraction was an independent predictor of PFS (p = 0.018) and OS (p = 0.022) in patients with stage IV PDAC treated with chemotherapy on multivariate analysis. Conclusions The ECV fraction determined by equilibrium contrast-enhanced DECT can potentially predict the survival of patients with stage IV PDAC treated with chemotherapy. Key Points • Extracellular volume fraction of stage IV pancreatic ductal adenocarcinoma determined by dual-energy CT was strongly correlated to that with single-energy CT (r = 0.965, p < 0.001). • Tumor extracellular volume fraction was an independent predictor of progression-free survival (p = 0.018) and overall survival (p = 0.022). • Extracellular volume fraction determined by dual-energy CT could be a useful imaging biomarker to predict the survival of patients with stage IV pancreatic ductal adenocarcinoma treated with chemotherapy.Keywords
This publication has 33 references indexed in Scilit:
- Contrast-Enhanced CT Quantification of the Hepatic Fractional Extracellular Space: Correlation With Diffuse Liver Disease SeverityAmerican Journal of Roentgenology, 2013
- Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic CancerPancreas, 2013
- Dual-source, dual-energy multidetector CT for the evaluation of pancreatic tumoursBritish Journal of Radiology, 2012
- Dual energy spectral CT imaging of insulinoma—Value in preoperative diagnosis compared with conventional multi-detector CTEuropean Journal of Radiology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomographyEuropean Journal of Radiology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modelingMagnetic Resonance Imaging, 2008
- Trends in the Treatment and Outcome of Pancreatic Cancer in the United StatesAnnals of Surgical Oncology, 2007
- Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2005